Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro

International Journal of Antimicrobial Agents

Volumn 35, Issue 4, 2010, Pages 347-356

  Harris, Mark R ^a   Coote, Peter J ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antifungals; Candidiasis; Combination therapy; Echinocandins; Synergy

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLIC PEPTIDE 6752; CYCLOPEPTIDE; DERMASEPTIN; GOMESIN; GS 14K 4; GS 14K4; MAGAININ 2; POLYPEPTIDE ANTIBIOTIC AGENT; RANALEXIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BODY WEIGHT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; HUMANS; KIDNEY; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 76749118428     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.11.021     Document Type: Article

References (31)

1. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., and Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29 (1999) 239-244
2. Enoch D., Ludlam H., and Brown N. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 55 (2006) 809-818
3. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37 (2003) 1172-1177
4. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
5. Pfaller M., and Diekema D. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20 (2007) 133-163
6. Hancock R., and Scott M. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 97 (2000) 8856-8861
7. Jenssen H., Hamill P., and Hancock R. Peptide antimicrobial agents. Clin Microbiol Rev 19 (2006) 491-511
8. Denning D. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
9. Harris M., Mora-Montes H.M., Gow N.A., and Coote P.L. Loss of mannosylphosphate from Candida albicans cell wall proteins results in enhanced resistance to the inhibitory effect of a cationic antimicrobial peptide via reduced peptide binding to the cell surface. Microbiology 155 (2009) 1058-1070
10. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 84 (1987) 5449-5453
11. Clark D., Durell S., Maloy W., and Zasloff M. Ranalexin. A novel antimicrobial peptide from bullfrog (Rana catesbeiana) skin, structurally related to the bacterial antibiotic, polymyxin. J Biol Chem 269 (1994) 10849-10855
12. Dartois V., Sanchez-Quesada J., Cabezas E., Chi E., Dubbelde C., Dunn C., et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother 49 (2005) 3302-3310
13. Kondejewski L.H., Lee D.L., Jelokhani-Niaraki M., Farmer S.W., Hancock R.E., and Hodges R.S. Optimization of microbial specificity in cyclic peptides by modulation of hydrophobicity within a defined structural framework. J Biol Chem 277 (2002) 67-74
14. Silva Jr. P.I., Daffre S., and Bulet P. Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the Tachyplesin family. J Biol Chem 275 (2000) 33464-33470
15. Mor A., Hani K., and Nicolas P. The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J Biol Chem 269 (1994) 31635-31641
16. Yang C.-R., Zhang Y., Jacob M.R., Khan S.I., Zhang Y.J., and Li X.C. Antifungal activity of C-27 steroidal saponins. Antimicrob Agents Chemother 50 (2006) 1710-1714
17. MacCallum D., and Odds F. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48 (2005) 151-161
18. MacCallum D.M., Castillo L., Nather K., Munro C.A., Brown A.J., Gow N.A., et al. Property differences among the four major Candida albicans strain clades. Eukaryot Cell 8 (2009) 373-387
19. Odds F. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52 (2003) 1
20. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., and Ghannoum M.A. Combination treatment of invasive fungal infections. Clin Microbiol Rev 18 (2005) 163-194
21. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
22. Arikan S., Lozano-Chui M., Paetznick V., and Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46 (2002) 245-247
23. Luque J., Clemons K., and Stevens D. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 47 (2003) 1452-1455
24. Olson J.A., Adler-Moore J.P., Smith P.J., and Proffitt R.T. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 49 (2005) 4895-4902
25. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they?. J Antimicrob Chemother 54 (2004) 854-869
26. Tanida T., Rao F., Hamada T., Ueta E., and Osaki T. Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect Immun 69 (2001) 3883-3890
27. Dannaoui E., Lortholary O., and Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 48 (2004) 970-978
28. Thompson III G.R., Wiederhold N.P., Vallor A.C., Villareal N.C., Lewis II J.S., and Patterson T.F. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 52 (2008) 3783-3785
29. Chamilos G., Lewis R., Albert N., and Kontoyiannis D.P. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51 (2007) 2257-2259
30. Wiederhold N.P., Kontoyiannis D.P., Prince R.A., and Lewis R.E. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 49 (2005) 5146-5148
31. Walker L.A., Munro C.A., de Bruijn I., Lenardon M.D., McKinnon A., and Gow N.A. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 4 (2008) 1000040